Application of tissue-specific NK and NKT cell activity for tumor immunotherapy

Journal of Autoimmunity

Volumn 33, Issue 3-4, 2009, Pages 275-281

  Subleski, Jeff J ^a   Wiltrout, Robert H ^a   Weiss, Jonathan M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Immunotherapy; Liver microenvironment; NK cells; NKT cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL THERAPY; DRUG POTENTIATION; EFFECTOR CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LIVER CANCER; LIVER METASTASIS; MICROENVIRONMENT; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; TISSUE INJURY; TISSUE SPECIFICITY; TUMOR REJECTION;

ANIMALS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIVER; LIVER NEOPLASMS; NATURAL KILLER T-CELLS; NEOPLASM METASTASIS;

EID: 71649115198     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2009.07.010     Document Type: Article

References (75)

1. Benlagha K., Wei D.G., Veiga J., Teyton L., and Bendelac A. Characterization of the early stages of thymic NKT cell development. J Exp Med 202 (2005) 485-492
2. Freud A.G., and Caligiuri M.A. Human natural killer cell development. Immunol Rev 214 (2006) 56-72
3. Vosshenrich C.A., Garcia-Ojeda M.E., Samson-Villeger S.I., Pasqualetto V., Enault L., Richard-Le Goff O., et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 7 (2006) 1217-1224
4. Perricone R., Perricone C., De Carolis C., and Shoenfeld Y. NK cells in autoimmunity: a two-edg'd weapon of the immune system. Autoimmun Rev 7 (2008) 384-390
5. Vas J., Mattner J., Richardson S., Ndonye R., Gaughan J.P., Howell A., et al. Regulatory roles for NKT cell ligands in environmentally induced autoimmunity. J Immunol 181 (2008) 6779-6788
6. Crispe I.N. The liver as a lymphoid organ. Annu Rev Immunol 27 (2009) 147-163
7. Fogler W.E., Volker K., Watanabe M., Wigginton J.M., Roessler P., Brunda M.J., et al. Recruitment of hepatic NK cells by IL-12 is dependent on IFN-gamma and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas. J Immunol 161 (1998) 6014-6021
8. Salazar-Mather T.P., Orange J.S., and Biron C.A. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J Exp Med 187 (1998) 1-14
9. Emoto M., Mittrucker H.W., Schmits R., Mak T.W., and Kaufmann S.H. Critical role of leukocyte function-associated antigen-1 in liver accumulation of CD4+NKT cells. J Immunol 162 (1999) 5094-5098
10. Geissmann F., Cameron T.O., Sidobre S., Manlongat N., Kronenberg M., Briskin M.J., et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 3 (2005) e113
11. Wiltrout R.H. Regulation and antimetastatic functions of liver-associated natural killer cells. Immunol Rev 174 (2000) 63-76
12. Yokoyama W.M., and Kim S. How do natural killer cells find self to achieve tolerance?. Immunity 24 (2006) 249-257
13. Lanier L.L., Corliss B., and Phillips J.H. Arousal and inhibition of human NK cells. Immunol Rev 155 (1997) 145-154
14. Cerwenka A., and Lanier L.L. Natural killer cells, viruses and cancer. Nat Rev Immunol 1 (2001) 41-49
15. Ortaldo J.R., Winkler-Pickett R., and Wiegand G. Activating Ly-49D NK receptors: expression and function in relation to ontogeny and Ly-49 inhibitor receptors. J Leukoc Biol 68 (2000) 748-756
16. Hayakawa Y., Kelly J.M., Westwood J.A., Darcy P.K., Diefenbach A., Raulet D., et al. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 169 (2002) 5377-5381
17. Savage P.B., Teyton L., and Bendelac A. Glycolipids for natural killer T cells. Chem Soc Rev 35 (2006) 771-779
18. Berzofsky J.A., and Terabe M. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 180 (2008) 3627-3635
19. Taniguchi M., Harada M., Kojo S., Nakayama T., and Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21 (2003) 483-513
20. Subleski J.J., Hall V.L., Back T.C., Ortaldo J.R., and Wiltrout R.H. Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res 66 (2006) 11005-11012
21. Terabe M., Swann J., Ambrosino E., Sinha P., Takaku S., Hayakawa Y., et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 202 (2005) 1627-1633
22. Halder R.C., Aguilera C., Maricic I., and Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 117 (2007) 2302-2312
23. Cheever M.A. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222 (2008) 357-368
24. Weiss J.M., Subleski J.J., Wigginton J.M., and Wiltrout R.H. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7 (2007) 1705-1721
25. Wigginton J.M., Lee J.K., Wiltrout T.A., Alvord W.G., Hixon J.A., Subleski J., et al. Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol 169 (2002) 4467-4474
26. Takeda K., Hayakawa Y., Atsuta M., Hong S., Van Kaer L., Kobayashi K., et al. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol 12 (2000) 909-914
27. Menard C., Blay J.Y., Borg C., Michiels S., Ghiringhelli F., Robert C., et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 69 (2009) 3563-3569
28. Fehniger T.A., Cai S.F., Cao X., Bredemeyer A.J., Presti R.M., French A.R., et al. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 26 (2007) 798-811
29. Nakagawa R., Nagafune I., Tazunoki Y., Ehara H., Tomura H., Iijima R., et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 166 (2001) 6578-6584
30. Nieda M., Nicol A., Koezuka Y., Kikuchi A., Lapteva N., Tanaka Y., et al. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 97 (2001) 2067-2074
31. de Rham C., Ferrari-Lacraz S., Jendly S., Schneiter G., Dayer J.M., and Villard J. The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther 9 (2007) R125
32. Zhang C., Zhang J., Niu J., Zhou Z., Zhang J., and Tian Z. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum Immunol 69 (2008) 490-500
33. Son Y.I., Dallal R.M., Mailliard R.B., Egawa S., Jonak Z.L., and Lotze M.T. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res 61 (2001) 884-888
34. Sawaki J., Tsutsui H., Hayashi N., Yasuda K., Akira S., Tanizawa T., et al. Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways. Int Immunol 19 (2007) 311-320
35. Martin-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5 (2004) 1260-1265
36. Wiltrout R.H., Herberman R.B., Zhang S.R., Chirigos M.A., Ortaldo J.R., Green Jr. K.M., et al. Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J Immunol 134 (1985) 4267-4275
37. Vermijlen D., Luo D., Froelich C.J., Medema J.P., Kummer J.A., Willems E., et al. Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway. J Leukoc Biol 72 (2002) 668-676
38. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95 (1998) 7556-7561
39. Ochi M., Ohdan H., Mitsuta H., Onoe T., Tokita D., Hara H., et al. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology 39 (2004) 1321-1331
40. Takeda K., Hayakawa Y., Smyth M.J., Kayagaki N., Yamaguchi N., Kakuta S., et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7 (2001) 94-100
41. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193 (2001) 661-670
42. Takeda K., Smyth M.J., Cretney E., Hayakawa Y., Yamaguchi N., Yagita H., et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol 214 (2001) 194-200
43. Crowe N.Y., Coquet J.M., Berzins S.P., Kyparissoudis K., Keating R., Pellicci D.G., et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 202 (2005) 1279-1288
44. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1 (2000) 515-520
45. Crowe N.Y., Smyth M.J., and Godfrey D.I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196 (2002) 119-127
46. Ambrosino E., Terabe M., Halder R.C., Peng J., Takaku S., Miyake S., et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 179 (2007) 5126-5136
47. Bahjat K.S., Prell R.A., Allen H.E., Liu W., Lemmens E.E., Leong M.L., et al. Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease. J Immunol 179 (2007) 7376-7384
48. Smyth M.J., Swann J., Kelly J.M., Cretney E., Yokoyama W.M., Diefenbach A., et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med 200 (2004) 1325-1335
49. Watanabe M., Fenton R.G., Wigginton J.M., McCormick K.L., Volker K.M., Fogler W.E., et al. Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production. J Immunol 163 (1999) 1943-1950
50. Ortaldo J.R., Winkler-Pickett R.T., Bere Jr. E.W., Watanabe M., Murphy W.J., and Wiltrout R.H. In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells. J Immunol 175 (2005) 693-699
51. Kim C.H., Johnston B., and Butcher E.C. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 100 (2002) 11-16
52. Pilaro A.M., Taub D.D., McCormick K.L., Williams H.M., Sayers T.J., Fogler W.E., et al. TNF-alpha is a principal cytokine involved in the recruitment of NK cells to liver parenchyma. J Immunol 153 (1994) 333-342
53. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 (1997) 1626-1629
54. Kitamura H., Iwakabe K., Yahata T., Nishimura S., Ohta A., Ohmi Y., et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189 (1999) 1121-1128
55. Carnaud C., Lee D., Donnars O., Park S.H., Beavis A., Koezuka Y., et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163 (1999) 4647-4650
56. Smyth M.J., Wallace M.E., Nutt S.L., Yagita H., Godfrey D.I., and Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 201 (2005) 1973-1985
57. Adam C., King S., Allgeier T., Braumuller H., Luking C., Mysliwietz J., et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 106 (2005) 338-344
58. Tatsumi T., Takehara T., Yamaguchi S., Sasakawa A., Sakamori R., Ohkawa K., et al. Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor. Hepatology 45 (2007) 22-30
59. Park S.H., Kyin T., Bendelac A., and Carnaud C. The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol 170 (2003) 1197-1201
60. Smyth M.J., Thia K.Y., Street S.E., Cretney E., Trapani J.A., Taniguchi M., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191 (2000) 661-668
61. Cohen N.R., Garg S., and Brenner M.B. Antigen presentation by CD1 lipids, T cells, and NKT cells in microbial immunity. Adv Immunol 102 (2009) 1-94
62. Meroni P.L. Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. J Autoimmun 30 (2008) 99-103
63. Poletaev A.B., Stepanyuk V.L., and Gershwin M.E. Integrating immunity: the immunculus and self-reactivity. J Autoimmun 30 (2008) 68-73
64. Vollmers H.P., and Brandlein S. Natural antibodies and cancer. J Autoimmun 29 (2007) 295-302
65. Lutz H.U. Homeostatic roles of naturally occurring antibodies: an overview. J Autoimmun 29 (2007) 287-294
66. Lang K.S., Burow A., Kurrer M., Lang P.A., and Recher M. The role of the innate immune response in autoimmune disease. J Autoimmun 29 (2007) 206-212
67. Papadimitraki E.D., Bertsias G.K., and Boumpas D.T. Toll like receptors and autoimmunity: a critical appraisal. J Autoimmun 29 (2007) 310-318
68. Peng Y., Martin D.A., Kenkel J., Zhang K., Ogden C.A., and Elkon K.B. Innate and adaptive immune response to apoptotic cells. J Autoimmun 29 (2007) 303-309
69. Yamagata T., Benoist C., and Mathis D. A shared gene-expression signature in innate-like lymphocytes. Immunol Rev 210 (2006) 52-66
70. Zigmond E., Shalev Z., Pappo O., Alper R., Zolotarov L., and Ilan Y. NKT lymphocyte polarization determined by microenvironment signaling: a role for CD8+ lymphocytes and beta-glycosphingolipids. J Autoimmun 31 (2008) 188-195
71. Pear W.S., Tu L., and Stein P.L. Lineage choices in the developing thymus: choosing the T and NKT pathways. Curr Opin Immunol 16 (2004) 167-173
72. Mackay I.R., Leskovsek N.V., and Rose N.R. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 30 (2008) 5-11
73. Whittingham S., Rowley M.J., and Gershwin M.E. A tribute to an outstanding immunologist - Ian Reay Mackay. J Autoimmun 31 (2008) 197-200
74. Gershwin M.E. Bone marrow transplantation, refractory autoimmunity and the contributions of Susumu Ikehara. J Autoimmun 30 (2008) 105-107
75. Blank M., and Gershwin M.E. Autoimmunity: from the mosaic to the kaleidoscope. J Autoimmun 30 (2008) 1-4